Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cell Administration (REALIST-COVID) Phase 2 Randomised Controlled Trial (2022)
Attributed to:
Mesenchymal stem cell-derived extracellular vesicles as a cell-free therapy for ARDS.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5285
Publication URI: http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5285
Type: Conference/Paper/Proceeding/Abstract